about
Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding.In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.Mitotic arrest induced by a novel family of DNA topoisomerase II inhibitors.Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemiaAchilles' heel of triple negative cancerTransautocrine signaling by membrane neuregulins requires cell surface targeting, which is controlled by multiple domainsAntitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancerPhospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors.Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.Neuregulins and cancer.Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic targetNeuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies.Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.Synthetic lethality interaction between Aurora kinases and CHEK1 inhibitors in ovarian cancer.Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.Targeting the EGF/HER Ligand-Receptor System in Cancer.In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells.Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases.N-terminal cleavage of proTGFalpha occurs at the cell surface by a TACE-independent activity.Multisite phosphorylation of P-Rex1 by protein kinase C.The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function.The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.Molecular pathways: P-Rex in cancer.Multifunctional role of Erk5 in multiple myeloma.Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications.Erk5 is activated and acts as a survival factor in mitosis.Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node.P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer.The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation.Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzymeCleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated formsTransforming growth factor-beta1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L(6)E(9) myoblastsNeuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer
P50
Q24531403-130EDA63-E6B8-4D60-AD4B-CD35AA7547B7Q31105168-D0A6EEDC-32BE-4DB5-B278-F86C41CE0180Q33560233-76ED7E05-376D-4C49-AAC7-4A3E1E04A809Q33612132-98094336-CC01-439F-BFAC-8333DE5CF838Q33728096-22CD1799-7B94-43EF-8AB1-1B26878161F7Q34781145-05B8F684-C3C6-447F-959D-92920C733B58Q35085158-DA086C02-0AD0-4182-9F93-5014097BF0C4Q36413944-0DF0F902-FDD2-49DF-8BFD-5131F7E4B1B3Q36544553-F324811A-4118-4FA5-B0E2-15792B5F14A3Q36544999-B3A0B86D-0892-430B-8DEC-85250312FC16Q36557500-97734EA0-9DC9-4573-90CF-8450657F696DQ37179990-E8D6F240-8EF8-41D1-8C1B-6EA475D8622AQ37182453-664B82D1-D564-4C58-9868-AE2E209EAFCAQ37564335-199CA715-6F82-4BB8-8AA8-38D16392D3D8Q37888979-4307AFF0-9A58-4575-807A-BD5B6CA3594DQ38605140-FAC13413-DD64-40B2-A732-8B6A1A13EF7DQ38773872-B9A72E54-AFA2-4099-BCB1-B0EAA9920B26Q38899794-B2CB2220-0FDC-4E6E-B25C-5FFD432BE373Q38968027-7371E7B0-F38E-44C7-B810-02DFF8BB2F5FQ39117994-6342B277-B82C-4A95-9555-B59F82150648Q39987410-4832127D-EF97-464F-BDED-47BA9E9F6479Q40740565-3C57352A-E276-4FF4-8F16-FB695A50FD07Q41956426-C4F9324B-59DE-4080-9A9D-8175F1E034BCQ42126557-07196362-F932-405D-B282-728BB6AC5B9BQ42131728-0740AA4B-FF01-4E7C-B7D6-FB6451EA8067Q44541080-928661FA-F056-4D84-AD0D-C13A96C3E5F1Q45163195-7925A680-7F6E-48A7-B92E-569056361B05Q45251392-54431C3D-86A2-4DD0-BB25-76F516BE4984Q47107645-FE870E58-0EB4-4ED1-B13C-693580FA651EQ53541523-0384CCDF-4DEB-4218-84B4-F20D5D483D9BQ54246808-AC867FCC-37FC-4047-8332-5368DDB1A34AQ54403803-75E871AD-8641-4F45-8676-A383E6777200Q55516477-D11F8CAD-3A29-49B1-B7B2-654E76FDDF57Q73204078-3D3357BB-B384-4D23-B136-AEA6739B23C0Q74673079-46803132-4327-459E-8BE0-C0CCE55BDB5CQ77793873-844F0B15-C1B6-40B8-93A1-A820159DDF4BQ80548331-3D893421-6DDC-4A3D-A518-F58736D81F90
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Juan C Montero
@ast
Juan C Montero
@en
Juan C Montero
@es
Juan C Montero
@nl
type
label
Juan C Montero
@ast
Juan C Montero
@en
Juan C Montero
@es
Juan C Montero
@nl
prefLabel
Juan C Montero
@ast
Juan C Montero
@en
Juan C Montero
@es
Juan C Montero
@nl
P106
P1153
7103015771
P21
P31
P496
0000-0003-4773-053X